Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
| Formerly | Isis Pharmaceuticals, Inc. |
|---|---|
| Company type | Public company |
Traded as |
|
| Industry | Biotechnology |
| Founded | 1989 |
| Founder | Stanley T. Crooke |
| Headquarters | Carlsbad, California, U.S. |
Key people | Brett P. Monia (CEO) Elizabeth L. Hougen (CFO) Joseph Loscalzo (Chairman of the Board) |
| Products | nusinersen, inotersen, volanesorsen, plazomicin, mipomersen |
| Revenue | US$587 million (2022) |
Net income | US$−270 million (2022) |
| Total assets | US$2.53 billion (2022) |
| Total equity | US$573 million (2022) |
Number of employees | 796 (December 2022) |
| Website | ionispharma |
| Footnotes / references | |
The company was named Isis Pharmaceuticals until December 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.